NORD Stock Overview
A biotechnology company, engages in the cancer diagnostic activities. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Norda ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 80.00 |
| 52 Week High | NOK 0 |
| 52 Week Low | NOK 0 |
| Beta | 0 |
| 1 Month Change | 91.85% |
| 3 Month Change | 92.77% |
| 1 Year Change | 95.12% |
| 3 Year Change | n/a |
| 5 Year Change | 300.00% |
| Change since IPO | -99.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| NORD | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | -2.8% |
| 1Y | 95.1% | -73.8% | -0.8% |
Return vs Industry: NORD exceeded the Norwegian Biotechs industry which returned -73.8% over the past year.
Return vs Market: NORD exceeded the Norwegian Market which returned -0.8% over the past year.
Price Volatility
| NORD volatility | |
|---|---|
| NORD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 14.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.9% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: NORD's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: Insufficient data to determine NORD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1 | Frode Westvold | www.nordasa.no |
Norda ASA, a biotechnology company, engages in the cancer diagnostic activities. The company is involved in the research and development of Genefec, a diagnostic screening test for colorectal cancer. It also invests and trades in securities, real estates, and other assets.
Norda ASA Fundamentals Summary
| NORD fundamental statistics | |
|---|---|
| Market cap | NOK 397.66m |
| Earnings (TTM) | NOK 100.24m |
| Revenue (TTM) | NOK 127.97m |
0.0x
P/E Ratio0.0x
P/S RatioIs NORD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NORD income statement (TTM) | |
|---|---|
| Revenue | NOK 127.97m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 127.97m |
| Other Expenses | NOK 27.73m |
| Earnings | NOK 100.24m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NORD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:13 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Norda ASA is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Espen Jørgensen | DNB Markets |
| John Savin | Edison Investment Research |
| Arvydas Noreika | Norne Securities AS |